ACY-1215
Drug
Celgene Corporation
Total Payments
$258,610
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $137,802 | 3 | 0 |
| 2017 | $120,807 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $258,610 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ACY1215-CL-BRST-PI-12809 - Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer | Celgene Corporation | $114,472 | 0 |
| Vitamin D fixed dose combination project | Celgene Corporation | $99,204 | 0 |
| ACY1215-CL-LYM-PI-12807 - A Phase Ib/II, Open-label, Multicenter Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients with Relapsed or Refractory Lymphoid Malignancies | Celgene Corporation | $14,571 | 0 |
| ACY1215-CL-OVAR-PI-12800 - A Phase 1b Study of weekly paclitaxel and oral ricolinostat for the treatment of recurrent platinum resistant ovarian, primary peritoneal, or fallopian tube cancer | Celgene Corporation | $8,760 | 0 |
| ACY1215-CL-BRST-PI-12809 | Celgene Corporation | $7,965 | 0 |
| ACE-MM-101 | Celgene Corporation | $7,738 | 0 |
| ACY-1215 | Celgene Corporation | $5,900 | 0 |
Top Doctors Receiving Payments for ACY-1215
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $258,610 | 7 |
Ad
Manufacturing Companies
- Celgene Corporation $258,610
Product Information
- Type Drug
- Total Payments $258,610
- Total Doctors 0
- Transactions 7
About ACY-1215
ACY-1215 is a drug associated with $258,610 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2018. In 2018, $137,802 was paid across 3 transactions to 0 doctors.
The most common payment nature for ACY-1215 is "Unspecified" ($258,610, 100.0% of total).
ACY-1215 is associated with 7 research studies, including "ACY1215-CL-BRST-PI-12809 - Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer" ($114,472).